NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired common stock of Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, inclusive. You are hereby notified that the class action lawsuit Dan Eller v. Vistagen Therapeutics, Inc., et al. (Case No. 3:26-cv-00427) has been commenced in the United States District Court for the No ...

VANCOUVER, BC / ACCESS Newswire / January 15, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company")is pleased to announce the launch of a controlled comparative animal study designed to evaluate cell-penetrating peptide (CPP) mediated, needle-free transdermal delivery of second generation GLP/GIP-based obesity therapies. This in vivo study represents an important next step towards advancing LIR's transdermal platform from design-stage planning into fu ...

On Jan. 15, 2026, investors took note of Anktiva's explosive sales ramp, its geographic expansion potential, and a possible new indication.NASDAQ : IBRXImmunityBioToday's Change( 30.80 %) $ 0.93Current Price$ 3.95Key Data PointsMarket Cap$3.0BDay's Range$ 3.07 - $ 3.9952wk Range$ 1.83 - $ 4.27Volume72MAvg Vol12MGross Margin80.41 %ImmunityBio (IBRX +30.80%), a cancer and infectious-disease drug developer, closed Thursday at $3.95, up 30.79% for the session. The stock jumped after preliminary 2025 results hig ...

PresentationGood afternoon. Thank you all for joining us here today. My name is Henry Jiang. I'm with the banking team here at JPMorgan, and it's my pleasure to be introducing ALX Oncology today. Joining us on stage and presenting today will be Jason Lettmann, CEO; as well as Barbara Klencke, Chief Medical Officer. Just a reminder that we'll have time for questions at the end of the session. So please wait until then for any questions, and we'll get you a microphone. But without further ado, I'll pass it ov ...

Summary of Jaguar Health FY Conference Call Company Overview - **Company Name**: Jaguar Health (NasdaqCM: JAGX) - **Subsidiary**: Napo Pharmaceuticals - **Key Product**: Crofelemer (brand name Mytesi), FDA-approved for chronic diarrhea in HIV/AIDS patients and chemotherapy-induced diarrhea in dogs under the brand name Canalevia-CA1 [4][5] Core Points and Arguments - **Product Development**: Jaguar Health focuses on drug development from plants traditionally used in tropical areas, with crofelemer being a first-in-class FDA-approved anti-secretory agent [4][5] - **Exclusivity**: The company holds over 150 patents and has exclusivity due to the FDA's botanical guidance, which prevents generics from entering the market [5] - **Recent Licensing Agreement**: An exclusive license agreement with FuturePak could be worth up to $38 million, including an upfront payment of $16 million and potential milestone payments [6] - **Sales Strategy**: Jaguar has transitioned its commercial responsibilities for Mytesi and Canalevia to FuturePak, allowing it to focus on its pipeline, particularly in rare diseases [11][12] Pipeline Focus - **Rare Disease Programs**: Jaguar is concentrating on ultra-rare diseases, specifically microvillus inclusion disease (MVID) and short bowel syndrome (SBS), with potential FDA filings by the end of 2026 [8][11] - **Market Potential**: The SBS market is estimated to be over $5 billion, with some estimates as high as $12 billion [12] - **Clinical Trials**: Ongoing trials for MVID and SBS are showing promising results, with significant reductions in parenteral nutrition for patients [16][25] Regulatory Pathways - **Breakthrough Designation**: The company is pursuing breakthrough therapy designation from the FDA, which could expedite the approval process for its rare disease treatments [28][29] - **Prime Designation in Europe**: This designation would facilitate communication and speed up the regulatory process across the EU [29] Canalevia-CA1 Update - **FDA Approval**: Canalevia-CA1 received conditional approval for chemotherapy-induced diarrhea in dogs, with ongoing studies required for full approval [32][33] - **Clinical Trial Funding**: Funds from the licensing agreement and grants will support the clinical trial for Canalevia-CA1 [34] Key Milestones for 2026 - **Clinical Trials**: Completion of MVID and SBS trials, with expectations for breakthrough and prime designations [38] - **Business Development**: Focus on securing business development deals independent of Mytesi and Canalevia, targeting rare disease indications [38] Additional Insights - **Patient Impact**: The company emphasizes the importance of supportive care in treating chronic conditions, particularly in the HIV community [10][11] - **Manufacturing as Profit Center**: Jaguar continues to manufacture crofelemer, which has become a profit center due to its commercialization by FuturePak [8] This summary encapsulates the key points discussed during the Jaguar Health FY Conference Call, highlighting the company's strategic focus, product pipeline, and market opportunities.

HUNTSVILLE, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ PlatformTM drug optimization technology, received a notice from the New York Stock Exchange ("NYSE") that it is below the continued listing criteria under Sections 1003(a)(i) and (ii) of the NYSE's listing standard ...

As filed with the Securities and Exchange Commission on January 15, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRINITY BIOTECH PLC (Exact name of registrant as specified in its charter) (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer Ireland 2835 Not Applicable incorporation or organization) Classification Code Number) Identification Number) IDA Business Park Bray, County Wicklow, ...

PresentationGood morning, everyone. My name is [Mary Lou], and I'm one of the associates on the healthcare investment banking team at JPMorgan. It's my pleasure to introduce our next presentation from ADC Therapeutics. I'm joined by the company's CEO, Ameet Mallik, who will give a presentation on the business, followed by a Q&A session. Thank you very much for being here. And with that, I'll turn it over to you.Ameet MallikCEO & Director Thank you very much. It's a pleasure to be here with all of you today, ...

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts public offering of 5,366,726 units. Each unit consists of one common share (or one pre-funded warrant (“Pre-Funded Warrant”) in lieu thereof) and one warrant (the “Warran ...

Summary of ALX Oncology FY Conference Call Company Overview - **Company**: ALX Oncology (NasdaqGS:ALXO) - **Key Programs**: Evorpacept and ALX 2004, both in clinical stages and differentiated in their class [2][3] Core Industry Insights - **Focus on CD47**: Evorpacept targets CD47, a critical immune checkpoint in oncology, which has been challenging to target effectively [3][4] - **EGFR-targeted ADC**: ALX 2004 is a novel antibody-drug conjugate (ADC) targeting EGFR, designed to minimize on-target toxicity while maximizing efficacy [21][22] Key Data and Findings - **Evorpacept Data**: - Presented at SITC with promising results in gastric cancer (Aspen-06) showing a 65% response rate in CD47 overexpressing HER2-positive patients, a significant improvement over the control arm [12][14] - Combination studies with Rituxan and Evorpacept showed complete response rates of 83% and 92% in different settings [13] - **ALX 2004 Progress**: - Currently in phase one trials, with successful completion of initial dose cohorts and a focus on optimizing the linker payload for better delivery and efficacy [4][31] - Preclinical data indicates superior bystander effects and reduced toxicity compared to existing EGFR-targeted therapies [27][29] Market Opportunity - **HER2-positive Breast Cancer**: - Estimated addressable patient population of 20,000, with a market opportunity valued between $2 billion to $4 billion [20] - Current treatments show response rates of 15% to 20%, indicating a significant unmet need for effective therapies post-HER2 treatment [19] Strategic Collaborations - **Partnerships**: Collaborations with Sanofi for combination studies in multiple myeloma, leveraging the high expression of CD47 in hematologic malignancies [46][47] Future Catalysts - **Upcoming Data Releases**: - Interim data for Evorpacept expected in Q3 2026, which will be crucial for validating the biomarker-driven approach [33] - Continued dose escalation and data sharing for ALX 2004 to elucidate its safety profile [34] Conclusion - ALX Oncology is positioned to potentially lead in the CD47 and EGFR-targeted therapy spaces with differentiated mechanisms and promising clinical data, addressing significant unmet medical needs in oncology [35][36]